Chip Davis has been out speaking with the media about the importance of generic and biosimilar medicines to patients and our economy. He is shining a light on the need to remedy anti-competitive roadblocks facing generics and biosimilars before they make it to market, and the challenges approved drugs meet when presented by consolidation on the demand side.
This recent New York Times Q/A “Generic Drug Prices Are Falling, but Are Consumers Benefiting?” quotes Chip and its content is informed by AAM data.
You can follow Chip on Twitter at @chesterdavisjr.
By Erica Klinger, AAM Marketing Director
